KR20240035837A - 약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물 - Google Patents
약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물 Download PDFInfo
- Publication number
- KR20240035837A KR20240035837A KR1020247004956A KR20247004956A KR20240035837A KR 20240035837 A KR20240035837 A KR 20240035837A KR 1020247004956 A KR1020247004956 A KR 1020247004956A KR 20247004956 A KR20247004956 A KR 20247004956A KR 20240035837 A KR20240035837 A KR 20240035837A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- membered
- heterocycloalkyl
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221905P | 2021-07-14 | 2021-07-14 | |
| US63/221,905 | 2021-07-14 | ||
| PCT/US2022/037029 WO2023287928A1 (en) | 2021-07-14 | 2022-07-13 | Bifunctional compounds for degrading btk with diminished imid activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240035837A true KR20240035837A (ko) | 2024-03-18 |
Family
ID=82799901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247004956A Pending KR20240035837A (ko) | 2021-07-14 | 2022-07-13 | 약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240336595A1 (https=) |
| EP (1) | EP4370123A1 (https=) |
| JP (1) | JP2024525797A (https=) |
| KR (1) | KR20240035837A (https=) |
| CN (1) | CN118019538A (https=) |
| AU (1) | AU2022310182A1 (https=) |
| CA (1) | CA3225367A1 (https=) |
| IL (1) | IL309796A (https=) |
| WO (1) | WO2023287928A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| JP2024524480A (ja) * | 2021-07-01 | 2024-07-05 | ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド | ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用 |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2025162210A1 (zh) * | 2024-02-04 | 2025-08-07 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
| WO2026005533A1 (ko) * | 2024-06-27 | 2026-01-02 | 한미약품 주식회사 | 신규한 이종이작용기 단백질 분해제 및 이의 용도 |
| CN120590386A (zh) * | 2025-05-30 | 2025-09-05 | 北京科莱博医药开发有限责任公司 | 一种喹喔啉类蛋白降解剂及其制备方法和应用 |
| CN120617259B (zh) * | 2025-06-05 | 2026-04-10 | 南昌大学第一附属医院 | Btk protac化合物nx-5948的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
-
2022
- 2022-07-13 AU AU2022310182A patent/AU2022310182A1/en active Pending
- 2022-07-13 CN CN202280061966.9A patent/CN118019538A/zh active Pending
- 2022-07-13 CA CA3225367A patent/CA3225367A1/en active Pending
- 2022-07-13 EP EP22751224.1A patent/EP4370123A1/en active Pending
- 2022-07-13 JP JP2024502035A patent/JP2024525797A/ja active Pending
- 2022-07-13 KR KR1020247004956A patent/KR20240035837A/ko active Pending
- 2022-07-13 WO PCT/US2022/037029 patent/WO2023287928A1/en not_active Ceased
- 2022-07-13 IL IL309796A patent/IL309796A/en unknown
- 2022-07-13 US US18/579,114 patent/US20240336595A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL309796A (en) | 2024-02-01 |
| WO2023287928A1 (en) | 2023-01-19 |
| EP4370123A1 (en) | 2024-05-22 |
| AU2022310182A1 (en) | 2024-02-01 |
| CN118019538A (zh) | 2024-05-10 |
| US20240336595A1 (en) | 2024-10-10 |
| CA3225367A1 (en) | 2023-01-19 |
| JP2024525797A (ja) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4069237B1 (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway | |
| KR20240035837A (ko) | 약화된 이미드 활성을 지닌 btk를 분해하기 위한 이작용성 화합물 | |
| KR102816424B1 (ko) | 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물 | |
| US12582722B2 (en) | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | |
| AU2022270089A1 (en) | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use | |
| US20240279202A1 (en) | Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use | |
| KR20240039001A (ko) | 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물 | |
| KR20260005915A (ko) | 유비퀴틴-프로테아좀 경로를 통한 braf 분해용 이중기능 화합물 | |
| US20250002489A1 (en) | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway | |
| WO2025111513A1 (en) | Compounds useful in the modulation of klhdc1 and klhdc2 activity | |
| BR122023025072A2 (pt) | Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma | |
| HK40081936A (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |